How did the approval affect NVO stock?

NVO stock rose 3% following the EU approval announcement.

What does this mean for LLY?

Retail traders believe LLY is behind Novo Nordisk in the oral weight-loss drug race, increasing pressure on the company.

When will oral Wegovy be available?

Novo Nordisk has not yet announced a commercial launch date or pricing.

EU Approval of Oral Wegovy Pill Lifts NVO Stock 3%

Novo Nordisk's oral Wegovy pill received approval across all EU member states, driving NVO stock up 3%. Retail traders note that LLY is 'clearly behind' its Danish counterpart.

July 15, 2026

2 min read

Source: Stocktwits

Key Numbers

stock jump

Novo Nordisk (NVO) shares jumped 3% today after the European Union approved its oral Wegovy pill for weight loss in all member states. The approval marks a significant expansion of the drug's availability, previously limited to injections.

The Product

The oral Wegovy pill is a new formulation of semaglutide, the active ingredient in Novo Nordisk's blockbuster weight-loss injection. It offers patients a needle-free alternative, potentially improving adherence and convenience.

Pricing and Availability

Pricing details and launch timelines have not been announced yet. Analysts expect the oral version to be priced competitively with the injectable form, though adjustments may occur per country.

Competition

Novo Nordisk faces competition from Eli Lilly (LLY), which is developing its own oral weight-loss drug. However, retail investors on Stocktwits note that LLY is "clearly behind" Novo Nordisk in the race for oral obesity treatments.

Potential Impact

The EU approval could solidify Novo Nordisk's leadership in the weight-loss drug market, projected to reach $100 billion by 2030. It also pressures LLY to accelerate its oral program to catch up.

Frequently Asked Questions

The oral Wegovy pill is a tablet form of semaglutide for weight loss, now approved in the EU as an alternative to injections.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.